Current status and research progress of surgical<b>-</b>induced liver volume hyperplasia_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

SU Yu ¹ , WU Hong ² ,  LIU Chang ^1,3

1. Division of Liver, Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
2. Liver Transplant Center, Organ Transplant Center, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
3. Department of Minimal Invasive Surgery, Shangjin Nanfu Hospital, Chengdu 610037, P. R. China;

Corresponding?author：

LIU Chang, Email: drliuchang@wchscu.cn

Keywords：

liver; volume hyperplasia; hepatic blood inflow

DOI：

10.7507/1007-9424.202109066

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To review the current status and progress of surgical methods for inducing hepatic volume hyperplasia. Method The procedures inducing liver volume regeneration in clinical practice, including portal vein embolization, liver venous deprivation, Yttrium-90 selective internal radiation therapy, and associating liver partition and portal vein ligation for staged hepatectomy were reviewed and summarized. Results All kinds of surgical methods to induce liver volume hyperplasia could effectively stimulate the increase in liver volume, which could provide more surgical opportunities for patients with too small future liver remnant, but there were differences in the degree of trauma, proliferation efficiency and popularization and acceptance. Conclusions All kinds of operations provide new hope for patients with too little residual liver volume after operation, and have good application scenarios. However, at present, there is no unified opinion on the comparison between the advantages and disadvantages of each operation and the best indication, which needs further study.

Citation： SU Yu, WU Hong, LIU Chang. Current status and research progress of surgical-induced liver volume hyperplasia. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2024, 31(1): 103-108. doi: 10.7507/1007-9424.202109066 Copy

1.	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
2.	中華人民共和國國家衛生健康委員會醫政醫管局. 原發性肝癌診療指南(2022年版). 中華肝臟病雜志, 2022, 30(4): 367-388.
3.	Memeo R, Conticchio M, Deshayes E, et al. Optimization of the future remnant liver: review of the current strategies in Europe. Hepatobiliary Surg Nutr, 2021, 10(3): 350-363.
4.	Dixon M, Cruz J, Sarwani N, et al. The future liver remnant : definition, evaluation, and management. Am Surg, 2021, 87(2): 276-286.
5.	Zhao HT, Cai JQ. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma. World J Gastroenterol, 2021, 27(47): 8069-8080.
6.	孫惠川, 沈英皓, 李小龍. 肝臟儲備功能與肝癌術式選擇. 中國實用外科雜志, 2018, 38(4): 473-476.
7.	Saxena R, Theise ND, Crawford JM. Microanatomy of the human liver-exploring the hidden interfaces. Hepatology, 1999, 30(6): 1339-1346.
8.	Michalopoulos GK, Bhushan B. Liver regeneration: biological and pathological mechanisms and implications. Nat Rev Gastroenterol Hepatol, 2021, 18(1): 40-55.
9.	Preziosi ME, Monga SP. Update on the mechanisms of liver regeneration. Semin Liver Dis, 2017, 37(2): 141-151.
10.	包勝嫻. 原發性肝癌ALPPS- Ⅰ圍術期肝臟血流動力學變化及其與剩余肝體積再生關系初步研究 . 南寧: 廣西醫科大學, 2023.
11.	Kawaguchi Y, Lillemoe HA, Vauthey JN. Dealing with an insufficient future liver remnant: Portal vein embolization and two-stage hepatectomy. J Surg Oncol, 2019, 119(5): 594-603.
12.	林偉鴻, 李凱. 肝切除術前肝臟儲備功能評估方式的新進展. 中華外科雜志, 2021, 59(5): 392-396.
13.	王榮福, 龐小溪, 劉敏, 等. ^99mTc-GSA肝受體顯像在肝功能評估臨床研究應用及進展. 世界華人消化雜志, 2017, 25(21): 1903-1909.
14.	Gavriilidis P, Edwin B, Pelanis E, et al. Navigated liver surgery: State of the art and future perspectives. Hepatobiliary Pancreat Dis Int, 2022, 21(3): 226-233.
15.	Kim D, Cornman-Homonoff J, Madoff DC. Preparing for liver surgery with “Alphabet Soup”: PVE, ALPPS, TAE-PVE, LVD and RL. Hepatobiliary Surg Nutr, 2020, 9(2): 136-151.
16.	陳乾, 林慧敏, 嚴福華. 磁共振成像評估肝功能儲備的研究進展. 診斷學理論與實踐, 2023, 22(2): 190-196.
17.	Poetter-Lang S, Bastati N, Messner A, et al. Quantification of liver function using gadoxetic acid-enhanced MRI. Abdom Radiol (NY), 2020, 45(11): 3532-3544.
18.	Rous P, Larimore LD. Relation of the portal blood to liver maintenance: a demonstration of liver atrophy conditional on compensation. J Exp Med, 1920, 31(5): 609-632.
19.	Kinoshita H, Sakai K, Hirohashi K, et al. Preoperative portal vein embolization for hepatocellular carcinoma. World J Surg, 1986, 10(5): 803-808.
20.	Vaupel P, Multhoff G. Blood supply and oxygenation status of the liver: from physiology to malignancy. Adv Exp Med Biol, 2022, 1395: 263-267.
21.	鄭本波, 黃文. 術前經皮選擇性門靜脈栓塞術在肝膽腫瘤的應用體會. 肝膽外科雜志, 2021, 29(1): 46-48.
22.	Isfordink CJ, Samim M, Braat MNGJA, et al. Portal vein ligation versus portal vein embolization for induction of hypertrophy of the future liver remnant: A systematic review and meta-analysis. Surg Oncol, 2017, 26(3): 257-267.
23.	Brüning R, Schneider M, Tiede M, et al. Ipsilateral access portal venous embolization (PVE) for preoperative hypertrophy exhibits low complication rates in Clavien-Dindo and CIRSE scales. CVIR Endovasc, 2021, 4(1): 41.
24.	Palavecino M, Chun YS, Madoff DC, et al. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery, 2009, 145(4): 399-405.
25.	Azoulay D, Castaing D, Krissat J, et al. Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. Ann Surg, 2000, 232(5): 665-672.
26.	Wakabayashi H, Ishimura K, Okano K, et al. Is preoperative portal vein embolization effective in improving prognosis after major hepatic resection in patients with advanced-stage hepatocellular carcinoma? Cancer, 2001, 92(9): 2384-2390.
27.	Glantzounis GK, Tokidis E, Basourakos SP, et al. The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review. Eur J Surg Oncol, 2017, 43(1): 32-41.
28.	趙文超, 吳印濤, 楊英祥, 等. 肝動脈插管化療栓塞聯合選擇性門靜脈栓塞后手術切除治療大肝癌的安全性和有效性觀察. 中華肝膽外科雜志, 2021, 27(3): 164-168.
29.	Kudo M, Ueshima K, Chan S, et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: A proof-of-concept study. Cancers (Basel), 2019, 11(8): 1084.
30.	徐彬, 李小龍, 朱小東, 等. 在接受侖伐替尼聯合PD-1抗體治療的不可切除肝細胞癌患者肝切除術前行門靜脈栓塞術的研究. 中華肝膽外科雜志, 2022, 28(1): 21-27.
31.	Hwang S, Lee SG, Ko GY, et al. Sequential preoperative ipsilateral hepatic vein embolization after portal vein embolization to induce further liver regeneration in patients with hepatobiliary malignancy. Ann Surg, 2009, 249(4): 608-616.
32.	Munene G, Parker RD, Larrigan J, et al. Sequential preoperative hepatic vein embolization after portal vein embolization for extended left hepatectomy in colorectal liver metastases. World J Surg Oncol, 2013, 11: 134.
33.	Guiu B, Chevallier P, Denys A, et al. Simultaneous trans-hepatic portal and hepatic vein embolization before major hepatectomy: the liver venous deprivation technique. Eur Radiol, 2016, 26(12): 4259-4267.
34.	劉暢, 張曉赟, 金諶, 等. 肝靜脈系統栓堵術在第二階段根治性肝癌切除術中的應用. 中國普外基礎與臨床雜志, 2019, 26(7): 841-846.
35.	王明宇, 梁英健, 尹兵, 等. 肝靜脈剝奪術—殘余肝臟不足時手術新思路. 中國實用外科雜志, 2020, 40(1): 102-105.
36.	Schadde E, Guiu B, Deal R, et al. Simultaneous hepatic and portal vein ligation induces rapid liver hypertrophy: A study in pigs. Surgery, 2019, 165(3): 525-533.
37.	Ko GY, Hwang S, Sung KB, et al. Interventional oncology: new options for interstitial treatments and intravascular approaches: right hepatic vein embolization after right portal vein embolization for inducing hypertrophy of the future liver remnant. J Hepatobiliary Pancreat Sci, 2010, 17(4): 410-412.
38.	侯昌龍, 王繼洲, 宋瑞鵬, 等. 術前肝靜脈剝奪術同期聯合精準肝動脈化療栓塞在原發性大肝癌二期切除中應用價值研究. 中國實用外科雜志, 2022, 42(6): 667-671.
39.	Cassese G, Troisi RI, Khayat S, et al. Liver venous deprivation versus associating liver partition and portal vein ligation for staged hepatectomy for colo-rectal liver metastases: a comparison of early and late kinetic growth rates, and perioperative and oncological outcomes. Surg Oncol, 2022, 43: 101812.
40.	Chebaro A, Buc E, Durin T, et al. Liver venous deprivation or associating liver partition and portal vein ligation for staged hepatectomy? A retrospective multicentric study. Ann Surg, 2021, 274(5): 874-880.
41.	Girard E, Trilling B, Chirica M. Comment on: liver venous deprivation (LVD) or associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)? A retrospective multicentric study. Hepatobiliary Surg Nutr, 2021, 10(5): 675-677.
42.	Guiu B, Quenet F, Panaro F, et al. Liver venous deprivation versus portal vein embolization before major hepatectomy: future liver remnant volumetric and functional changes. Hepatobiliary Surg Nutr, 2020, 9(5): 564-576.
43.	Gavriilidis P, Marangoni G, Ahmad J, et al. Simultaneous portal and hepatic vein embolization is better than portal embolization or ALPPS for hypertrophy of future liver remnant before major hepatectomy: A systematic review and network meta-analysis. Hepatobiliary Pancreat Dis Int, 2023, 22(3): 221-227.
44.	Panaro F, Giannone F, Riviere B, et al. Perioperative impact of liver venous deprivation compared with portal venous embolization in patients undergoing right hepatectomy: preliminary results from the pioneer center. Hepatobiliary Surg Nutr, 2019, 8(4): 329-337.
45.	B?ning G, Fehrenbach U, Auer TA, et al. Liver venous deprivation (LVD) versus portal vein embolization (PVE) alone prior to extended hepatectomy: A matched pair analysis. Cardiovasc Intervent Radiol, 2022, 45(7): 950-957.
46.	高潔, 劉曉明, 周文華, 等. ⁹⁰Y微球的研發現狀與應用研究. 同位素, 2022, 35(3): 189-199.
47.	Jakobs TF, Saleem S, Atassi B, et al. Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with ⁹⁰Yttrium microspheres. Dig Dis Sci, 2008, 53(9): 2556-2563.
48.	Teo JY, Allen JC, Ng DC, et al. A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with ⁹⁰Y. HPB (Oxford), 2016, 18(1): 7-12.
49.	Garlipp B, de Baere T, Damm R, et al. Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization. Hepatology, 2014, 59(5): 1864-1873.
50.	Teo JY, Goh BK. Contra-lateral liver lobe hypertrophy after unilobar ⁹⁰Y radioembolization: an alternative to portal vein embolization? World J Gastroenterol, 2015, 21(11): 3170-3173.
51.	Birgin E, Rasbach E, Seyfried S, et al. Contralateral liver hypertrophy and oncological outcome following radioembolization with ⁹⁰Y-microspheres: A systematic review. Cancers (Basel), 2020, 12(2): 294.
52.	Najafi A, Binkert CA. Transarterial radioembolization to impact liver volumetry: when and how. Cardiovasc Intervent Radiol, 2022, 45(11): 1646-1650.
53.	Garlipp B, Gibbs P, Van Hazel GA, et al. Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial. Br J Surg, 2019, 106(13): 1837-1846.
54.	Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg, 2012, 255(3): 405-414.
55.	周儉, 王征, 孫健, 等. 聯合肝臟離斷和門靜脈結扎的二步肝切除術. 中華消化外科雜志, 2013, 12(7): 485-489.
56.	李世思, 郭志唐, 陳章彬, 等. ALPPS治療肝臟腫瘤的研究進展. 肝膽胰外科雜志, 2021, 33(4): 253-257.
57.	劉允怡, 劉曉欣. 對“聯合肝臟離斷和門靜脈結扎的二步肝切除術”的述評. 中華消化外科雜志, 2013, 12(7): 481-484.
58.	楊奎, 陳擁軍. 聯合肝臟離斷和門靜脈結扎二步肝切除術的熱點與爭議. 中華普通外科雜志, 2018, 33(2): 172-175.
59.	Sparrelid E, Hasselgren K, R?sok BI, et al. How should liver hypertrophy be stimulated? A comparison of upfront associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) and portal vein embolization (PVE) with rescue possibility. Hepatobiliary Surg Nutr, 2021, 10(1): 1-8.
60.	王征, 樊嘉, 周儉. ALPPS在肝臟外科的應用前景. 肝膽外科雜志, 2015, 23(1): 1-2.
61.	蔡涵暉, 胡智明, 楊鴻國. 門靜脈栓塞術在計劃性肝切除中的臨床應用. 中華普通外科雜志, 2019, 34(2): 184-186.
62.	彭馳涵, 李川, 文天夫, 等. 原發性肝癌行ALPPS的適應證與禁忌證初探(附15例報道). 中國普外基礎與臨床雜志, 2015, 22(10): 1183-1186.
63.	陳偉, 梁力建. 聯合肝臟離斷和門靜脈結扎的二步肝切除術在肝臟腫瘤治療中的應用. 中華普通外科學文獻(電子版), 2014, 8(3): 237-240.
64.	文天夫. ALPPS在肝細胞癌治療中的地位. 中國普外基礎與臨床雜志, 2016, 23(1): 1-4.
65.	Petrowsky H, Gy?ri G, de Oliveira M, et al. Is partial-ALPPS safer than ALPPS? A single-center experience. Ann Surg, 2015, 261(4): e90-e92.
66.	Khajeh E, Ramouz A, Dooghaie Moghadam A, et al. Efficacy of technical modifications to the associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) procedure: A systematic review and meta-analysis. Ann Surg Open, 2022, 3(4): e221.
67.	閆加艷, 楊欣榮, 周儉. 聯合肝臟分隔和門靜脈結扎的二步肝切除術臨床與基礎研究進展. 中國普通外科雜志, 2023, 32(7): 967-976.
68.	Gringeri E, Boetto R, D’Amico FE, et al. Laparoscopic microwave ablation and portal vein ligation for staged hepatectomy (LAPS): a minimally invasive first-step approach. Ann Surg, 2015, 261(2): e42-e43.
69.	首志雄, 鄭達武, 梁泳榮, 等. 腹腔鏡輔助微波消融后行ALPPS治療原發性肝癌的臨床療效觀察. 中國普外基礎與臨床雜志, 2023, 30(8): 939-943.
70.	徐邦浩, 藍祝晶, 朱海, 等. 聯合肝實質分隔和門靜脈結扎的二步肝切除術式演變進展. 中國普外基礎與臨床雜志, 2023, 30(7): 870-876.
71.	周承匯, 羅慧, 李嘉榮, 等. 腹腔鏡輔助與開腹ALPPS治療肝癌的近期療效比較. 中國普通外科雜志, 2019, 28(3): 366-370.

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
2. 中華人民共和國國家衛生健康委員會醫政醫管局. 原發性肝癌診療指南(2022年版). 中華肝臟病雜志, 2022, 30(4): 367-388.
3. Memeo R, Conticchio M, Deshayes E, et al. Optimization of the future remnant liver: review of the current strategies in Europe. Hepatobiliary Surg Nutr, 2021, 10(3): 350-363.
4. Dixon M, Cruz J, Sarwani N, et al. The future liver remnant : definition, evaluation, and management. Am Surg, 2021, 87(2): 276-286.
5. Zhao HT, Cai JQ. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma. World J Gastroenterol, 2021, 27(47): 8069-8080.
6. 孫惠川, 沈英皓, 李小龍. 肝臟儲備功能與肝癌術式選擇. 中國實用外科雜志, 2018, 38(4): 473-476.
7. Saxena R, Theise ND, Crawford JM. Microanatomy of the human liver-exploring the hidden interfaces. Hepatology, 1999, 30(6): 1339-1346.
8. Michalopoulos GK, Bhushan B. Liver regeneration: biological and pathological mechanisms and implications. Nat Rev Gastroenterol Hepatol, 2021, 18(1): 40-55.
9. Preziosi ME, Monga SP. Update on the mechanisms of liver regeneration. Semin Liver Dis, 2017, 37(2): 141-151.
10. 包勝嫻. 原發性肝癌ALPPS- Ⅰ圍術期肝臟血流動力學變化及其與剩余肝體積再生關系初步研究 . 南寧: 廣西醫科大學, 2023.
11. Kawaguchi Y, Lillemoe HA, Vauthey JN. Dealing with an insufficient future liver remnant: Portal vein embolization and two-stage hepatectomy. J Surg Oncol, 2019, 119(5): 594-603.
12. 林偉鴻, 李凱. 肝切除術前肝臟儲備功能評估方式的新進展. 中華外科雜志, 2021, 59(5): 392-396.
13. 王榮福, 龐小溪, 劉敏, 等. ^99mTc-GSA肝受體顯像在肝功能評估臨床研究應用及進展. 世界華人消化雜志, 2017, 25(21): 1903-1909.
14. Gavriilidis P, Edwin B, Pelanis E, et al. Navigated liver surgery: State of the art and future perspectives. Hepatobiliary Pancreat Dis Int, 2022, 21(3): 226-233.
15. Kim D, Cornman-Homonoff J, Madoff DC. Preparing for liver surgery with “Alphabet Soup”: PVE, ALPPS, TAE-PVE, LVD and RL. Hepatobiliary Surg Nutr, 2020, 9(2): 136-151.
16. 陳乾, 林慧敏, 嚴福華. 磁共振成像評估肝功能儲備的研究進展. 診斷學理論與實踐, 2023, 22(2): 190-196.
17. Poetter-Lang S, Bastati N, Messner A, et al. Quantification of liver function using gadoxetic acid-enhanced MRI. Abdom Radiol (NY), 2020, 45(11): 3532-3544.
18. Rous P, Larimore LD. Relation of the portal blood to liver maintenance: a demonstration of liver atrophy conditional on compensation. J Exp Med, 1920, 31(5): 609-632.
19. Kinoshita H, Sakai K, Hirohashi K, et al. Preoperative portal vein embolization for hepatocellular carcinoma. World J Surg, 1986, 10(5): 803-808.
20. Vaupel P, Multhoff G. Blood supply and oxygenation status of the liver: from physiology to malignancy. Adv Exp Med Biol, 2022, 1395: 263-267.
21. 鄭本波, 黃文. 術前經皮選擇性門靜脈栓塞術在肝膽腫瘤的應用體會. 肝膽外科雜志, 2021, 29(1): 46-48.
22. Isfordink CJ, Samim M, Braat MNGJA, et al. Portal vein ligation versus portal vein embolization for induction of hypertrophy of the future liver remnant: A systematic review and meta-analysis. Surg Oncol, 2017, 26(3): 257-267.
23. Brüning R, Schneider M, Tiede M, et al. Ipsilateral access portal venous embolization (PVE) for preoperative hypertrophy exhibits low complication rates in Clavien-Dindo and CIRSE scales. CVIR Endovasc, 2021, 4(1): 41.
24. Palavecino M, Chun YS, Madoff DC, et al. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery, 2009, 145(4): 399-405.
25. Azoulay D, Castaing D, Krissat J, et al. Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. Ann Surg, 2000, 232(5): 665-672.
26. Wakabayashi H, Ishimura K, Okano K, et al. Is preoperative portal vein embolization effective in improving prognosis after major hepatic resection in patients with advanced-stage hepatocellular carcinoma? Cancer, 2001, 92(9): 2384-2390.
27. Glantzounis GK, Tokidis E, Basourakos SP, et al. The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review. Eur J Surg Oncol, 2017, 43(1): 32-41.
28. 趙文超, 吳印濤, 楊英祥, 等. 肝動脈插管化療栓塞聯合選擇性門靜脈栓塞后手術切除治療大肝癌的安全性和有效性觀察. 中華肝膽外科雜志, 2021, 27(3): 164-168.
29. Kudo M, Ueshima K, Chan S, et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: A proof-of-concept study. Cancers (Basel), 2019, 11(8): 1084.
30. 徐彬, 李小龍, 朱小東, 等. 在接受侖伐替尼聯合PD-1抗體治療的不可切除肝細胞癌患者肝切除術前行門靜脈栓塞術的研究. 中華肝膽外科雜志, 2022, 28(1): 21-27.
31. Hwang S, Lee SG, Ko GY, et al. Sequential preoperative ipsilateral hepatic vein embolization after portal vein embolization to induce further liver regeneration in patients with hepatobiliary malignancy. Ann Surg, 2009, 249(4): 608-616.
32. Munene G, Parker RD, Larrigan J, et al. Sequential preoperative hepatic vein embolization after portal vein embolization for extended left hepatectomy in colorectal liver metastases. World J Surg Oncol, 2013, 11: 134.
33. Guiu B, Chevallier P, Denys A, et al. Simultaneous trans-hepatic portal and hepatic vein embolization before major hepatectomy: the liver venous deprivation technique. Eur Radiol, 2016, 26(12): 4259-4267.
34. 劉暢, 張曉赟, 金諶, 等. 肝靜脈系統栓堵術在第二階段根治性肝癌切除術中的應用. 中國普外基礎與臨床雜志, 2019, 26(7): 841-846.
35. 王明宇, 梁英健, 尹兵, 等. 肝靜脈剝奪術—殘余肝臟不足時手術新思路. 中國實用外科雜志, 2020, 40(1): 102-105.
36. Schadde E, Guiu B, Deal R, et al. Simultaneous hepatic and portal vein ligation induces rapid liver hypertrophy: A study in pigs. Surgery, 2019, 165(3): 525-533.
37. Ko GY, Hwang S, Sung KB, et al. Interventional oncology: new options for interstitial treatments and intravascular approaches: right hepatic vein embolization after right portal vein embolization for inducing hypertrophy of the future liver remnant. J Hepatobiliary Pancreat Sci, 2010, 17(4): 410-412.
38. 侯昌龍, 王繼洲, 宋瑞鵬, 等. 術前肝靜脈剝奪術同期聯合精準肝動脈化療栓塞在原發性大肝癌二期切除中應用價值研究. 中國實用外科雜志, 2022, 42(6): 667-671.
39. Cassese G, Troisi RI, Khayat S, et al. Liver venous deprivation versus associating liver partition and portal vein ligation for staged hepatectomy for colo-rectal liver metastases: a comparison of early and late kinetic growth rates, and perioperative and oncological outcomes. Surg Oncol, 2022, 43: 101812.
40. Chebaro A, Buc E, Durin T, et al. Liver venous deprivation or associating liver partition and portal vein ligation for staged hepatectomy? A retrospective multicentric study. Ann Surg, 2021, 274(5): 874-880.
41. Girard E, Trilling B, Chirica M. Comment on: liver venous deprivation (LVD) or associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)? A retrospective multicentric study. Hepatobiliary Surg Nutr, 2021, 10(5): 675-677.
42. Guiu B, Quenet F, Panaro F, et al. Liver venous deprivation versus portal vein embolization before major hepatectomy: future liver remnant volumetric and functional changes. Hepatobiliary Surg Nutr, 2020, 9(5): 564-576.
43. Gavriilidis P, Marangoni G, Ahmad J, et al. Simultaneous portal and hepatic vein embolization is better than portal embolization or ALPPS for hypertrophy of future liver remnant before major hepatectomy: A systematic review and network meta-analysis. Hepatobiliary Pancreat Dis Int, 2023, 22(3): 221-227.
44. Panaro F, Giannone F, Riviere B, et al. Perioperative impact of liver venous deprivation compared with portal venous embolization in patients undergoing right hepatectomy: preliminary results from the pioneer center. Hepatobiliary Surg Nutr, 2019, 8(4): 329-337.
45. B?ning G, Fehrenbach U, Auer TA, et al. Liver venous deprivation (LVD) versus portal vein embolization (PVE) alone prior to extended hepatectomy: A matched pair analysis. Cardiovasc Intervent Radiol, 2022, 45(7): 950-957.
46. 高潔, 劉曉明, 周文華, 等. ⁹⁰Y微球的研發現狀與應用研究. 同位素, 2022, 35(3): 189-199.
47. Jakobs TF, Saleem S, Atassi B, et al. Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with ⁹⁰Yttrium microspheres. Dig Dis Sci, 2008, 53(9): 2556-2563.
48. Teo JY, Allen JC, Ng DC, et al. A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with ⁹⁰Y. HPB (Oxford), 2016, 18(1): 7-12.
49. Garlipp B, de Baere T, Damm R, et al. Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization. Hepatology, 2014, 59(5): 1864-1873.
50. Teo JY, Goh BK. Contra-lateral liver lobe hypertrophy after unilobar ⁹⁰Y radioembolization: an alternative to portal vein embolization? World J Gastroenterol, 2015, 21(11): 3170-3173.
51. Birgin E, Rasbach E, Seyfried S, et al. Contralateral liver hypertrophy and oncological outcome following radioembolization with ⁹⁰Y-microspheres: A systematic review. Cancers (Basel), 2020, 12(2): 294.
52. Najafi A, Binkert CA. Transarterial radioembolization to impact liver volumetry: when and how. Cardiovasc Intervent Radiol, 2022, 45(11): 1646-1650.
53. Garlipp B, Gibbs P, Van Hazel GA, et al. Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial. Br J Surg, 2019, 106(13): 1837-1846.
54. Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg, 2012, 255(3): 405-414.
55. 周儉, 王征, 孫健, 等. 聯合肝臟離斷和門靜脈結扎的二步肝切除術. 中華消化外科雜志, 2013, 12(7): 485-489.
56. 李世思, 郭志唐, 陳章彬, 等. ALPPS治療肝臟腫瘤的研究進展. 肝膽胰外科雜志, 2021, 33(4): 253-257.
57. 劉允怡, 劉曉欣. 對“聯合肝臟離斷和門靜脈結扎的二步肝切除術”的述評. 中華消化外科雜志, 2013, 12(7): 481-484.
58. 楊奎, 陳擁軍. 聯合肝臟離斷和門靜脈結扎二步肝切除術的熱點與爭議. 中華普通外科雜志, 2018, 33(2): 172-175.
59. Sparrelid E, Hasselgren K, R?sok BI, et al. How should liver hypertrophy be stimulated? A comparison of upfront associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) and portal vein embolization (PVE) with rescue possibility. Hepatobiliary Surg Nutr, 2021, 10(1): 1-8.
60. 王征, 樊嘉, 周儉. ALPPS在肝臟外科的應用前景. 肝膽外科雜志, 2015, 23(1): 1-2.
61. 蔡涵暉, 胡智明, 楊鴻國. 門靜脈栓塞術在計劃性肝切除中的臨床應用. 中華普通外科雜志, 2019, 34(2): 184-186.
62. 彭馳涵, 李川, 文天夫, 等. 原發性肝癌行ALPPS的適應證與禁忌證初探(附15例報道). 中國普外基礎與臨床雜志, 2015, 22(10): 1183-1186.
63. 陳偉, 梁力建. 聯合肝臟離斷和門靜脈結扎的二步肝切除術在肝臟腫瘤治療中的應用. 中華普通外科學文獻(電子版), 2014, 8(3): 237-240.
64. 文天夫. ALPPS在肝細胞癌治療中的地位. 中國普外基礎與臨床雜志, 2016, 23(1): 1-4.
65. Petrowsky H, Gy?ri G, de Oliveira M, et al. Is partial-ALPPS safer than ALPPS? A single-center experience. Ann Surg, 2015, 261(4): e90-e92.
66. Khajeh E, Ramouz A, Dooghaie Moghadam A, et al. Efficacy of technical modifications to the associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) procedure: A systematic review and meta-analysis. Ann Surg Open, 2022, 3(4): e221.
67. 閆加艷, 楊欣榮, 周儉. 聯合肝臟分隔和門靜脈結扎的二步肝切除術臨床與基礎研究進展. 中國普通外科雜志, 2023, 32(7): 967-976.
68. Gringeri E, Boetto R, D’Amico FE, et al. Laparoscopic microwave ablation and portal vein ligation for staged hepatectomy (LAPS): a minimally invasive first-step approach. Ann Surg, 2015, 261(2): e42-e43.
69. 首志雄, 鄭達武, 梁泳榮, 等. 腹腔鏡輔助微波消融后行ALPPS治療原發性肝癌的臨床療效觀察. 中國普外基礎與臨床雜志, 2023, 30(8): 939-943.
70. 徐邦浩, 藍祝晶, 朱海, 等. 聯合肝實質分隔和門靜脈結扎的二步肝切除術式演變進展. 中國普外基礎與臨床雜志, 2023, 30(7): 870-876.
71. 周承匯, 羅慧, 李嘉榮, 等. 腹腔鏡輔助與開腹ALPPS治療肝癌的近期療效比較. 中國普通外科雜志, 2019, 28(3): 366-370.

Previous Article
Mechanism of immune checkpoint inhibitors related adverse events
Next Article
Diagnosis and treatment of 131 adult patients with bronchopulmonary sequestration: A retrospective analysis

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Current status and research progress of surgical-induced liver volume hyperplasia

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content